Diffuse large B-cell lymphoma

Experience from a tertiary care center in North India

Rohan Khera, Snigdha Jain, Lalit Kumar, S. Thulkar, M. Vijayraghwan, R. Dawar

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Limited information is available from developing countries regarding clinico-pathological presentation of diffuse large B-cell lymphoma (DLBCL). We undertook a retrospective case record study to determine the clinicolaboratory characteristics, treatment outcomes, and prognostic factors for DLBCL and additionally analyzed percentage distribution and patient characteristics for other major subtypes of non-Hodgkin's lymphoma (NHL). DLBCL, constituting 59.3% of all NHL cases, was the predominant subtype. For DLBCL, males:females ratio was 2.7:1 and the median age at presentation was 47 years. Lymphadenopathy was present in 57% patients and B symptoms in 56.7%. A total of 49.3% of patients had Ann Arbor Stage IV disease. Significant differences were observed between favorable (international prognostic index [IPI]-0, 1, and 2) and unfavorable prognosis groups (IPI-3, 4, and 5) with regards to mean hemoglobin levels (P\0.005), platelet counts (P\0.05), serum albumin levels (P\0.05), and erythrocyte sedimentation rates (P\0.005), thereby suggesting their role as prognostic markers in our population. The median event free survival was 32 months (95% CI: 0-92 months) and the median overall survival was 47 months (95% CI: 3-100 months). Among total NHL, the earlier age of onset, male dominant sex ratio, and higher frequency of B symptoms sets apart NHL in Indian population from that in the developed countries.

Original languageEnglish (US)
Pages (from-to)310-318
Number of pages9
JournalMedical Oncology
Volume27
Issue number2
DOIs
StatePublished - Jun 1 2010

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Tertiary Care Centers
Non-Hodgkin's Lymphoma
India
Blood Sedimentation
Sex Ratio
Platelet Count
Age of Onset
Developed Countries
Serum Albumin
Population
Developing Countries
Disease-Free Survival
Survival

Keywords

  • Diffuse large B-cell lymphoma
  • India
  • Lymphoma
  • Non-Hodgkin's lymphoma
  • Prognostic factors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Diffuse large B-cell lymphoma : Experience from a tertiary care center in North India. / Khera, Rohan; Jain, Snigdha; Kumar, Lalit; Thulkar, S.; Vijayraghwan, M.; Dawar, R.

In: Medical Oncology, Vol. 27, No. 2, 01.06.2010, p. 310-318.

Research output: Contribution to journalArticle

Khera, R, Jain, S, Kumar, L, Thulkar, S, Vijayraghwan, M & Dawar, R 2010, 'Diffuse large B-cell lymphoma: Experience from a tertiary care center in North India', Medical Oncology, vol. 27, no. 2, pp. 310-318. https://doi.org/10.1007/s12032-009-9211-2
Khera, Rohan ; Jain, Snigdha ; Kumar, Lalit ; Thulkar, S. ; Vijayraghwan, M. ; Dawar, R. / Diffuse large B-cell lymphoma : Experience from a tertiary care center in North India. In: Medical Oncology. 2010 ; Vol. 27, No. 2. pp. 310-318.
@article{13817b90b51d44ed9277e97cefc2f8a8,
title = "Diffuse large B-cell lymphoma: Experience from a tertiary care center in North India",
abstract = "Limited information is available from developing countries regarding clinico-pathological presentation of diffuse large B-cell lymphoma (DLBCL). We undertook a retrospective case record study to determine the clinicolaboratory characteristics, treatment outcomes, and prognostic factors for DLBCL and additionally analyzed percentage distribution and patient characteristics for other major subtypes of non-Hodgkin's lymphoma (NHL). DLBCL, constituting 59.3{\%} of all NHL cases, was the predominant subtype. For DLBCL, males:females ratio was 2.7:1 and the median age at presentation was 47 years. Lymphadenopathy was present in 57{\%} patients and B symptoms in 56.7{\%}. A total of 49.3{\%} of patients had Ann Arbor Stage IV disease. Significant differences were observed between favorable (international prognostic index [IPI]-0, 1, and 2) and unfavorable prognosis groups (IPI-3, 4, and 5) with regards to mean hemoglobin levels (P\0.005), platelet counts (P\0.05), serum albumin levels (P\0.05), and erythrocyte sedimentation rates (P\0.005), thereby suggesting their role as prognostic markers in our population. The median event free survival was 32 months (95{\%} CI: 0-92 months) and the median overall survival was 47 months (95{\%} CI: 3-100 months). Among total NHL, the earlier age of onset, male dominant sex ratio, and higher frequency of B symptoms sets apart NHL in Indian population from that in the developed countries.",
keywords = "Diffuse large B-cell lymphoma, India, Lymphoma, Non-Hodgkin's lymphoma, Prognostic factors",
author = "Rohan Khera and Snigdha Jain and Lalit Kumar and S. Thulkar and M. Vijayraghwan and R. Dawar",
year = "2010",
month = "6",
day = "1",
doi = "10.1007/s12032-009-9211-2",
language = "English (US)",
volume = "27",
pages = "310--318",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Diffuse large B-cell lymphoma

T2 - Experience from a tertiary care center in North India

AU - Khera, Rohan

AU - Jain, Snigdha

AU - Kumar, Lalit

AU - Thulkar, S.

AU - Vijayraghwan, M.

AU - Dawar, R.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Limited information is available from developing countries regarding clinico-pathological presentation of diffuse large B-cell lymphoma (DLBCL). We undertook a retrospective case record study to determine the clinicolaboratory characteristics, treatment outcomes, and prognostic factors for DLBCL and additionally analyzed percentage distribution and patient characteristics for other major subtypes of non-Hodgkin's lymphoma (NHL). DLBCL, constituting 59.3% of all NHL cases, was the predominant subtype. For DLBCL, males:females ratio was 2.7:1 and the median age at presentation was 47 years. Lymphadenopathy was present in 57% patients and B symptoms in 56.7%. A total of 49.3% of patients had Ann Arbor Stage IV disease. Significant differences were observed between favorable (international prognostic index [IPI]-0, 1, and 2) and unfavorable prognosis groups (IPI-3, 4, and 5) with regards to mean hemoglobin levels (P\0.005), platelet counts (P\0.05), serum albumin levels (P\0.05), and erythrocyte sedimentation rates (P\0.005), thereby suggesting their role as prognostic markers in our population. The median event free survival was 32 months (95% CI: 0-92 months) and the median overall survival was 47 months (95% CI: 3-100 months). Among total NHL, the earlier age of onset, male dominant sex ratio, and higher frequency of B symptoms sets apart NHL in Indian population from that in the developed countries.

AB - Limited information is available from developing countries regarding clinico-pathological presentation of diffuse large B-cell lymphoma (DLBCL). We undertook a retrospective case record study to determine the clinicolaboratory characteristics, treatment outcomes, and prognostic factors for DLBCL and additionally analyzed percentage distribution and patient characteristics for other major subtypes of non-Hodgkin's lymphoma (NHL). DLBCL, constituting 59.3% of all NHL cases, was the predominant subtype. For DLBCL, males:females ratio was 2.7:1 and the median age at presentation was 47 years. Lymphadenopathy was present in 57% patients and B symptoms in 56.7%. A total of 49.3% of patients had Ann Arbor Stage IV disease. Significant differences were observed between favorable (international prognostic index [IPI]-0, 1, and 2) and unfavorable prognosis groups (IPI-3, 4, and 5) with regards to mean hemoglobin levels (P\0.005), platelet counts (P\0.05), serum albumin levels (P\0.05), and erythrocyte sedimentation rates (P\0.005), thereby suggesting their role as prognostic markers in our population. The median event free survival was 32 months (95% CI: 0-92 months) and the median overall survival was 47 months (95% CI: 3-100 months). Among total NHL, the earlier age of onset, male dominant sex ratio, and higher frequency of B symptoms sets apart NHL in Indian population from that in the developed countries.

KW - Diffuse large B-cell lymphoma

KW - India

KW - Lymphoma

KW - Non-Hodgkin's lymphoma

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=77956906938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956906938&partnerID=8YFLogxK

U2 - 10.1007/s12032-009-9211-2

DO - 10.1007/s12032-009-9211-2

M3 - Article

VL - 27

SP - 310

EP - 318

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 2

ER -